AARDEX Group is a trusted global partner for pharmaceutical companies, specializing in the digital measurement and management of medication adherence in clinical trials.

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide.

The opportunity

To develop a connected drug delivery system for oral solid pills, taken daily, that is easy to use and improves the clinical experience for Parkinson’s patients and their family members/lay caregivers.

The impact

After each study, the team used the data and root cause analyses to identify and implement design improvements to mitigate use errors. The findings from the study were used to make design changes to the blister wallet, the instructions for use (IFU), and the MEMS® Mobile screen design, content, and overall app workflow.

The resource

Biogen performed three formative usability studies recruiting Parkinson’s patients and their caregivers to complete simulated use tasks. Data collection included:

- Observational data of performance and interactions
- Qualitative user feedback (structured & open-ended)
- Assessments by experienced human factors SMEs

The usability validation component of DiMe’s V3+ framework describes the interplay between formative testing and design. AARDEX and its partners, Westrock and Schreiner, together with Biogen, took an iterative approach to design all elements of the system, including:

- Blister wallet electronics design and on-packaging labeling elements
- User interface of MEMS® Mobile (screen design, content, app navigation)

Biogen, with input from Aardex, also used an iterative approach to develop:

- Graphic instructions for intended use by patients & training by clinicians
- Instructional video to aid user independence and train clinical personnel

Usability of digital adherence solutions is the key to success in achieving comprehensive patient data on drug exposure.”

— Oana Paun
Quality Assurance Manager,
AARDEX Group

— Johanna Schoss
Human Factors Engineer,
Pharmaceutical Operations and Technology Division,
Biogen

Biogen

— Johanna Schoss
Human Factors Engineer,
Pharmaceutical Operations and Technology Division,
Biogen

Biogen

— Oana Paun
Quality Assurance Manager,
AARDEX Group

Biogen
AARDEX Group is a trusted global partner for pharmaceutical companies, specializing in the digital measurement and management of medication adherence in clinical trials.

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide.

Usability of digital adherence solutions is the key to success in achieving comprehensive patient data on drug exposure.”

— Oana Paun
Quality Assurance Manager, AARDEX Group

— Johanna Schoss
Human Factors Engineer, Pharmaceutical Operations and Technology Division, Biogen

The opportunity

To deploy a connected drug delivery system in a Phase 3 clinical study with Parkinson's patients to increase rates of medication adherence and enable clinical staff to remotely monitor, intervene, and assist in real-time as needed.

The resource

Biogen conducted three usability studies of the digital blister wallet and MEMS® Mobile application. The final, summative usability study was designed to provide validation that iterative improvements based on formative testing were effective in making the digital blister wallet system safe, effective, and highly usable for Parkinson's patients enrolled in a Phase 3 clinical study.

The usability evaluation component of DiMe's V3+ framework provided a structured approach to usability testing for AARDEX and its partners to identify improvements through data-driven insights, and ensured the design was optimized to better suit the needs of users.

The impact

The system was introduced into the Phase 3 clinical study for summative testing. The goal was to assess if the final instructions for use (IFU) and system design were safe, easy to use, and effective in minimizing use errors with the digital blister wallet system. Although only a small number of patients were given the system, the resulting data indicated that these Parkinson's patients were able to use the blister wallet and scan their data effectively.